Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry
Molho, Eric , Stacy, Mark, Gillard, Patrick, Charles, David , Schwartz, Marc , Brin, Mitchell F. , Adler, Charles H. , Jankovic, Joseph J.

Movement Disorders Clinical Practice | December 16, 2015 | Volume: 3 | Issue: 2 | Pages: 130-138

10.1002/mdc3.12238 | PMID 27774495 Get It

Abstract Background Cervical dystonia is thought to result in high disease burden, but limited information exists on its impact on employment and work productivity. We utilized data from the Cervical Dystonia Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (ClinicalTrials.gov identifier: NCT 00836017) to assess the impact of cervical dystonia on employment and work productivity and examine the effect of onabotulinumtoxinA treatments on work productivity. Methods Subjects completed a questionnaire on employment status and work productivity at baseline and final visit. Baseline data were examined by severity of cervical dystonia, predominant subtype, presence of pain, prior exposure to botulinum toxin, and/or utility of a sensory trick. Work productivity results at baseline and final visit were compared in subjects who were toxin‐naïve at baseline and received three onabotulinumtoxinA treatments. Results Of 1,038 subjects, 42.8% were employed full‐ or part‐time, 6.1% unemployed, 32.7% retired, and 11.8% disabled. Of those currently employed, cervical dystonia affected work status of 26.0%, caused 29.8% to miss work in the past month (mean, 5.1 ± 6.4 days), and 57.8% reported decreased productivity. Half of those unemployed were employed when symptoms began, and 38.5% attributed lost employment to cervical dystonia. Pain, increasing severity, and anterocollis/retrocollis had the largest effects on work status/productivity. Preliminary analyses showed that absenteeism and presenteeism were significantly decreased following onabotulinumtoxinA treatments in the subpopulation that was toxin‐naïve at baseline. Conclusions This analysis confirms the substantial negative impact of cervical dystonia on employment, with cervical dystonia‐associated pain being a particularly important driver. OnabotulinumtoxinA treatment appears to improve work productivity.
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke
Ungprasert, Patompong , Matteson, Eric L. , Thongprayoon, Charat

Stroke | December 16, 2015 | Volume: 47 | Issue: 2 | Pages: 356-364

10.1161/strokeaha.115.011678 | PMID 26670086 Get It

Background and Purpose— The association between hemorrhagic stroke and use of nonsteroidal anti-inflammatory drugs (NSAIDs) is not well established. We conducted a systematic review and meta-analysis of observation studies to further characterize this possible association. Methods— Case–control and cohort studies that reported odds ratio, relative risk, hazard ratio, or standardized incidence ratio comparing risk of hemorrhagic stroke among NSAIDs users versus nonusers were systematically searched. Point estimates from each study were extracted. Pooled risk ratios (RR) and 95% confidence intervals (CI) for all NSAIDs and individual NSAIDs were calculated using random-effect, generic inverse variance method. Results— Ten studies were identified and included in our data analysis. As a single group, NSAIDs use was associated with a small but insignificant risk of hemorrhagic stroke with the pooled RR of 1.09 (95% CI, 0.98–1.22). Individual NSAIDs analysis revealed a significantly increased risk among diclofenac and meloxicam users (RR 1.27; 95% CI, 1.02–1.59 and RR 1.27; 95% CI, 1.08–1.50, respectively). The risk estimate for rofecoxib users was higher, but statistically nonsignificant (RR 1.35; 95% CI, 0.88–2.06). Conclusions— Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users.
Lumen-apposing covered self-expanding metal stent for management of benign gastrointestinal strictures
Buttar, Navtej , Gostout, Christopher J., Levy, Michael J. , Martin, John A. , Petersen, Bret T. , Topazian, Mark , Song, Louis Wong Kee, Dayyeh, Barham Abu, Buttar, Navtej S, Gostout, Christopher, Martin, John, Petersen, Bret, Wong Kee Song, Louis M, Abu Dayyeh, Barham K, Majumder, Shounak , Levy, Michael J.

Endoscopy International Open | December 16, 2015 | Volume: 04 | Issue: 01 | Pages: E96-E101

10.1055/s-0041-108195 | PMID 26793793 Get It

Reciprocating Reentry
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | December 15, 2015 | Volume: 8 | Issue: 6 | Pages: 1512-1513

10.1161/circep.115.003241 | PMID 26671937 Get It

Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy
Hunter, Jacob B. , Carlson, Matthew L. , Sweeney, Alex D. , Tombers, Nicole M. , Wanna, George B. , Driscoll, Colin L. W., Haynes, David S. , Hunter, Jacob B

Otolaryngology–Head and Neck Surgery | December 15, 2015 | Volume: 154 | Issue: 3 | Pages: 513-517

10.1177/0194599815621738 | PMID 26671902 Get It

ObjectiveTo describe surgical outcomes and perioperative complications in patients taking antiplatelet and anticoagulation medications while undergoing cochlear implantation.Study DesignCase series with chart review.SettingTwo tertiary otologic referral center.Subjects and MethodsForty‐six adult patients (2005‐2014) who underwent cochlear implantation while on perioperative antiplatelet and/or anticoagulation therapy without interruption. Outcomes included estimated intraoperative blood loss, perception of increased difficulty secondary to bleeding, and postoperative complications attributable to continuing anticoagulation or antiplatelet therapy.ResultsThe cases of 46 patients (mean age, 69.5 years; 30.2% female) were analyzed. Of these, 39 patients were taking aspirin, 10 warfarin, and 7 clopidogrel. Aside from 3 (6.5%) patients with postoperative bruising without hematoma and 1 patient (2.2%) who reported self‐resolving oral cavity blood, no intraoperative or postoperative complications occurred in any patient that could be ascribed to antiplatelet or anticoagulant use.ConclusionThese data demonstrate that the risk of perioperative complications from continued antiplatelet or anticoagulation therapy is low. For subjects who are at risk of major complications (eg, deep venous thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident) from temporary medication cessation, continuing antiplatelet or anticoagulation therapy through the perioperative period is an appropriate strategy.
Universal Sinus Computed Tomography Protocol for Diagnostic Imaging and Intraoperative Navigation
Hoxworth, Joseph M. , Lal, Devyani

Allergy & Rhinology | December 15, 2015 | Volume: 6 | Issue: 3 | Pages: No page available

10.2500/ar.2015.6.0134 | PMID 26686204 Get It

Background Sinus computed tomography (CT) is performed for the diagnosis of paranasal sinus disease and to assess response to medical therapy. In addition, sinus CT is used for intraoperative imaging guidance. Multiple CTs increase cost and radiation exposure. Objective To determine potential cost savings and radiation dose reduction that result from the use of a single universal sinus CT protocol for diagnostic imaging and intraoperative navigation. Materials and Methods For sinus CT at the authors' institution, a single imaging protocol was begun and deemed acceptable by neuroradiologists and surgeons for diagnostic imaging and intraoperative guidance. The electronic medical record was queried over a 4-year period to determine the number of sinus CTs performed, dose-length products, referring providers' specialties, percentage of CTs used for intraoperative navigation, and the elapsed time between CT and surgery. Results A total of 6187 sinus CTs were performed by using a 64-detector scanner during the study period (2759 women and 3428 men; 53.6 ± 16.7 years [mean ± SD]), and 596 endoscopic sinus surgery cases used imaging guidance, for which all the CTs were deemed technically adequate. The mean dose-length product for the CTs was 338.4 ± 31.9 mGy-cm (mean ± SD). Of the 3702 sinus CTs ordered by nonotolaryngology providers, 167 surgeries with intraoperative navigation (4.5%) were performed. A higher percentage of CT referrals from sinus surgeons (23.9%) and other otolaryngology providers (11.4%) was used for imaging guidance (p < 0.0001). The time interval between sinus CT and surgery was greatest for nonotolaryngology providers (63.1 days, p < 0.01). Based on Medicare reimbursement, the total estimated saving was $147,628. Conclusions Adopting a single universal sinus CT protocol for diagnostic imaging and intraoperative navigation can be an effective means of decreasing cost and radiation exposure. However, successful implementation must take into account multiple practice-based considerations.
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms
Scherber, Robyn M. , Senyak, Zhenya, Dueck, Amylou C. , Clark, Matthew M. , Boxer, Michael , Geyer, Holly L. , McCallister, Archie, Cotter, Mary, Husen, Barbara Van, Harrison, Claire , Dueck, A. C. , Kosiorek, Heidi , Mesa, Ruben A.

Cancer | December 15, 2015 | Volume: 122 | Issue: 3 | Pages: 477-485

10.1002/cncr.29753 | PMID 26670597 Get It

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70‐item, Internet‐based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index ( P <.001), current use of alcohol ( P <.001), and current tobacco use ( P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week ( P <.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome ( P = .006), diabetes mellitus ( P = .045), fibromyalgia ( P < 0.001), chronic fatigue syndrome ( P = .006), and chronic kidney disease ( P = .02). Current use of antidepressants ( P <.001), antihistamines ( P = .0276), antianxiety medications ( P = .0357), and prescription pain medications ( P <.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms ( P <.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477–485. © 2015 American Cancer Society .
Comparison of Time Trends of Cardiovascular Disease Risk Factors and Framingham Risk Score Between Patients With and Without Acute Coronary Syndrome Undergoing Percutaneous Intervention Over the Last 17 Years: From the Mayo Clinic Percutaneous Coronary Int
Flammer, Andreas J. , Li, Jing , Lennon, Ryan J. , Delacroix, Sinny , Kim, Hyun-Soo , Lee, Moo‐Sik , Lerman, Amir

Clinical Cardiology | December 15, 2015 | Volume: 38 | Issue: 12 | Pages: 747-756

10.1002/clc.22484 | PMID 26671071 Get It

ABSTRACTBackgroundThe objective of this study was to investigate cardiovascular disease risk factor (cvRF) profiles and compare their trends over 17 years in patients with and without acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).HypothesisTime trends of cvRF are different between ACS and non‐ACS patients.MethodsThis study was a time‐trend analysis from 1994 to 2010 within the Mayo Clinic PCI registry. Outcome measures were incidence and prevalence of cvRF, including the Framingham Risk Score (FRS), at the time of admission for PCI.ResultsAge of non‐ACS patients was higher than that of ACS patients, and age distribution slightly shifted toward older age in both groups (P for trend <0.001). There was no difference in FRS between the 2 groups; however, 10‐year cardiovascular disease risk (%) remained higher in non‐ACS than in ACS patients, decreasing over time. Diastolic blood pressure and high‐density lipoprotein cholesterol were higher in non‐ACS patients, but total cholesterol and low‐density lipoprotein cholesterol were higher in ACS patients, with an improving trend over time. Prevalence of diabetes mellitus, hypertension, and history of hypercholesterolemia were higher in non‐ACS patients, increasing over time. Smoking did not change over time. Use of most medications increased over time in both groups.ConclusionsMost cvRFs and their time trends exhibited statistically significant differences between ACS and non‐ACS patients, except systolic blood pressure, body mass index, and history of myocardial infarction. A new risk‐factor profile assessment may be needed for stratification of PCI patients according to ACS and non‐ACS status. Clinical and public‐health interventions should consider different approaches to ACS and non‐ACS patients.
Atypical cartilaginous tumor/chondrosarcoma, grade 1, of the mastoid in three family members: A new entity
Frisch, Christopher D., Inwards, Carrie Y., Lalich, Ian J. , Carter, Jodi M. , Neff, Brian A., Carter, Jodi

The Laryngoscope | December 15, 2015 | Volume: 126 | Issue: 9 | Pages: E310-E313

10.1002/lary.25802 | PMID 26667047 Get It

Liver capsule: Cholangiocarcinoma (CCA)
Ilyas, Sumera I. , Gores, Gregory J.

Hepatology | December 15, 2015 | Volume: 63 | Issue: 4 | Pages: 1356-1356

10.1002/hep.28401 | PMID 26667406 Get It